Evidence map›Paper›PMID 37847874›Full record

ArticleJournal of clinical oncology : official journal of the American Society of Clinical Oncology2023

Poly(ADP-ribose) Polymerase Inhibitor Combinations in First-Line Metastatic Castration-Resistant Prostate Cancer: Increasing Toxicity With Unclear Benefits.

Ravi A Madan, Fatima Karzai, David J VanderWeele, Heather H Cheng, Johann S de Bono

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 2 countries.

Ravi A MadanGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD.ORCID 0000-0001-5106-8636
Fatima KarzaiGenitourinary Malignancies Branch, National Cancer Institute, Bethesda, MD.ORCID 0000-0002-3244-1332
David J VanderWeeleDivision of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL.ORCID 0000-0003-4576-5034
Heather H ChengDivision of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA.ORCID 0000-0002-1365-0702
Johann S de BonoThe Institute of Cancer Research, London, United Kingdom.ORCID 0000-0002-2034-595X
National Cancer Institute · USNorthwestern University · USRoyal Marsden NHS Foundation Trust · GBUniversity of Washington Medical Center · US

Funding

Medical Research Council MR/W018217/1
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antineoplastic AgentsProstatic Neoplasms, Castration-ResistantHumansMalePoly(ADP-ribose) Polymerase InhibitorsAntineoplastic AgentsPoly(ADP-ribose) Polymerase Inhibitors

Identifiers

PMID37847874
PMCPMC10861006
OpenAlexW4387699952

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.